ArticleScientific reports2016
Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 104 citations in OpenAlex.
- Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomised controlled trial.The European respiratory journal · 2026Trial
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- Proteogenomic verifies targets underlying erythromycin alleviate neutrophil extracellular traps-induced inflammation.Respiratory research · 2025Article
- Recent advances in the prevention and treatment of respiratory syncytial virus disease.The Journal of general virology · 2025Review
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
- Effects ofFrontiers in allergy · 2025Article
- Azithromycin mitigates human rhinovirus impact on barrier integrity and function in non-diseased airway epithelium.Frontiers in cell and developmental biology · 2025Article
- COVID-19 in Relation to Chronic Antihistamine Prescription.Microorganisms · 2024Article
- Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.Signal transduction and targeted therapy · 2023Review
- Antihistamines as an early treatment for Covid-19.Heliyon · 2023Article
- Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients.African health sciences · 2022Article
- Azithromycin through the Lens of the COVID-19 Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.Antiviral research · 2022Article
- The effect of vitamin D, magnesium and zinc supplements on interferon signaling pathways and their relationship to control SARS-CoV-2 infection.Clinical and molecular allergy : CMA · 2021Review
- Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.European journal of pharmacology · 2021Review
- Azithromycin in the Successful Management of COVID-19: A Family Physician's Perspective.Cureus · 2021Article
- Simultaneous electrochemical detection of azithromycin and hydroxychloroquine based on VSMicrochemical journal : devoted to the application of microtechniques in all branches of science · 2021Article
- Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.Pulmonary pharmacology & therapeutics · 2021Observational
- Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.Life sciences · 2021Article
- Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19.Arabian journal of chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhinovirus infection is a major cause of chronic obstructive pulmonary disease (COPD) exacerbations and may contribute to the development into severe stages of COPD. The macrolide antibiotic azithromycin may exert anti-viral actions and has been reported to reduce exacerbations in COPD. However, little is known about its anti-viral actions on bronchial epithelial cells at clinically relevant concentrations. Primary bronchial epithelial cells from COPD donors and healthy individuals were treated continuously with azithromycin starting 24 h before infection with rhinovirus RV16. Expression of interferons, RIG-I like helicases, pro-inflammatory cytokines and viral load were analysed. Azithromycin transiently increased expression of IFNβ and IFNλ1 and RIG-I like helicases in un-infected COPD cells. Further, azithromycin augmented RV16-induced expression of interferons and RIG-I like helicases in COPD cells but not in healthy epithelial cells. Azithromycin also decreased viral load. However, it only modestly altered RV16-induced pro-inflammatory cytokine expression. Adding budesonide did not reduce interferon-inducing effects of azithromycin. Possibly by inducing expression of RIG-I like helicases, azithromycin increased rhinovirus-induced expression of interferons in COPD but not in healthy bronchial epithelium. These effects would reduce bronchial viral load, supporting azithromycin's emerging role in prevention of exacerbations of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.